Impurity Qualification (ICH Q3A/Q3B)
ICH Q3A(R2) sets reporting, identification, and qualification thresholds for organic impurities in new drug substances; ICH Q3B(R2) applies the same structural logic to degradation products in new drug products. Both guidelines scale their thresholds to the maximum daily dose of the drug, so the same impurity level can trigger different obligations in a low-dose versus a high-dose product.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 19 LINKSQ3A and Q3B scale the burden of proof to the dose a patient receives: the same impurity at the same level can need only a number, a structure, or a safety justification depending on how much drug is taken.
06 · QUALITY MATURITY — IMPURITY QUALIFICATION (ICH Q3A/Q3B), REACTIVE TO ADAPTIVE
Impurities are whatever the chromatogram shows above the integration threshold, and the specification lists them as unspecified.
Thresholds are applied and impurities above them are named, but the applicable threshold was read from the guideline without recomputing it against the current daily dose.
Thresholds are calculated from the actual maximum daily dose, each impurity above them carries identification or qualification evidence, and degradants are tracked separately from process impurities.
The impurity profile is maintained across route, supplier and formulation changes, and the specification reflects what the process now produces rather than what it once did.
Impurity formation is understood mechanistically, so control moves upstream into the process and the specification narrows as understanding deepens rather than staying at the threshold.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 4
Derived from the 4 standards SPEQ maps to this subject, across 1 regulatory body: ICH.
RECORDS & OBJECTIVE EVIDENCE
- The impurity profile distinguishing process impurities from degradation products
- Threshold calculations tied to the maximum daily dose actually approved
- Structural identification data for impurities above the identification threshold
- Qualification evidence — toxicological or clinical exposure — for impurities above the qualification threshold
- Forced degradation and stability data establishing which degradants form and under what conditions
COMMON INSPECTION FINDINGS
- Thresholds applied from the guideline text without recalculation against the product’s daily dose
- Impurities reported as unspecified when their level required identification
- Degradation products and process impurities managed as one undifferentiated list
- A qualification argument resting on exposure in batches that were never actually administered
- The profile unchanged in the specification after a route or supplier change that altered it
Three Escalating Thresholds
Q3A and Q3B structure impurity control around three ascending thresholds. A reporting threshold sets the lowest level at which an impurity must be quantified and reported at all. An identification threshold, set higher, is the level above which the impurity’s chemical structure is expected to be elucidated rather than simply quantified. A qualification threshold, higher still, is the level above which safety data — comparison to a qualified historical level, relevant published toxicology data, or in some cases a dedicated safety study — is expected to justify that the impurity at that level does not pose an unacceptable risk. Each threshold is set relative to the drug’s maximum daily dose, which is why the guidelines cannot be applied correctly using a single fixed percentage regardless of dose.
Qualification Pathways, in Ascending Burden
An impurity above the qualification threshold can be qualified in more than one way. The lightest path is showing the impurity is already present at or below the observed level in a previously qualified, comparable product or process. Where that comparison is unavailable, relevant published toxicological data on the specific impurity may suffice. Where neither exists, a dedicated nonclinical safety study becomes necessary — the most resource-intensive route, and one development programs generally try to avoid by controlling the impurity below the qualification threshold in the first place.
The Explicit Carve-Out for Mutagenic Impurities
SPEQ interpretation: Q3A and Q3B are written for impurities in general, but they explicitly exclude impurities that are, or are suspected to be, mutagenic — those are instead controlled under ICH M7’s Threshold of Toxicological Concern framework, which applies a more conservative, non-dose-proportional logic because a threshold safety margin cannot be assumed the way it can for an ordinary impurity. Applying the ordinary Q3A/Q3B qualification pathway to a structurally alerting impurity is a scope error, not a lighter-touch alternative.
Relationship to Elemental and Solvent Impurities
Organic impurities and degradation products sit alongside, but are governed separately from, the elemental-impurity limits in ICH Q3D and the residual-solvent limits elsewhere in ICH’s Q3-series guidelines. A drug substance’s overall impurity control strategy — tying all of these categories together into one coherent, risk-based justification — is developed under the broader framework of ICH Q11.
FREQUENTLY ASKED
Why do impurity thresholds change with dose?
The thresholds are set relative to a patient’s total daily exposure to the drug, so the same absolute impurity level represents a much smaller or larger exposure risk depending on how much of the drug is actually dosed each day.
What is the easiest way to qualify an impurity above the qualification threshold?
Demonstrating the impurity is already present at or below the observed level in a previously qualified, comparable product or process is generally the lightest path; a dedicated safety study is reserved for when no such comparison or relevant published data exists.
Do mutagenic impurities follow the Q3A/Q3B qualification pathway?
No — impurities that are, or are suspected to be, mutagenic are explicitly excluded from the standard Q3A/Q3B pathway and controlled instead under ICH M7’s Threshold of Toxicological Concern framework.
Is a degradation product the same thing as an impurity for these purposes?
Q3A addresses impurities in the drug substance itself; Q3B addresses degradation products that form in the drug product over time — related concepts governed by parallel but separate threshold structures.